Avita Medical Ltd (RCEL)
NASDAQ:RCEL
Want to see RCEL full AI Analyst Report?
RCEL Stock Chart & Stats
$4.80
-$5.13(-36.49%)
At close: 4:00 PM EST
$4.80
-$5.13(-36.49%)
Day’s Range― - ―
52-Week Range$3.22 - $7.12
Previous CloseN/A
Volume824.49K
Average Volume (3M)263.27K
Market Cap
$120.34M
Enterprise Value$101.24M
Total Cash (Recent Filing)$14.26M
Total Debt (Recent Filing)$1.98M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 06, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-35.96
Shares Outstanding30,776,690
10 Day Avg. Volume241,116
30 Day Avg. Volume263,266
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-5.77
Price to Sales (P/S)1.34
P/FCF Ratio-2.99
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue1.40
Enterprise Value/Gross Profit1.72
Enterprise Value/Ebitda-2.68
Forecast
1Y Price Target
$7.17Price Target Upside49.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$82.79M
Bulls Say, Bears Say
Bulls Say
High Revenue Growth And Strong Gross MarginsSustained top-line momentum (TTM revenue +~103% YoY) and consistently high gross margins (low-80% range, RECELL ~85%) indicate durable unit economics and recurring procedure-driven consumable demand. This supports scalable revenue leverage as adoption grows across burn centers and hospitals over months.
Reimbursement Normalization And Product ExpansionMedicare Administrative Contractors publishing payment rates and RECELL reimbursement normalization materially lowers payor uncertainty, enabling procedure recovery. New SKUs (RECELL GO mini) and regulatory clearances expand addressable markets and permit durable unit-volume growth across more clinical settings and geographies.
Government Partnership And Financing HeadroomA BARDA preparedness agreement provides multi-year guaranteed revenue and program validation, while a Perceptive credit facility with manageable covenants and disclosed headroom eases near-term funding strain. Combined with recent opex cuts, these elements improve execution optionality during commercialization scaling.
Bears Say
Persistent Negative Free Cash FlowConsistent negative operating and free cash flow (TTM ≈ -$31M) means the business continues to rely on external capital to fund growth and operations. Over a 2–6 month horizon this increases financing and dilution risk and constrains the pace of commercial investment and inventory build for broader adoption.
Negative Shareholders' Equity And Weakened Balance SheetAccumulated losses that produced negative shareholders' equity materially reduce financial flexibility. This structural erosion makes new financing more dilutive or costly, limits covenant room with lenders, and heightens execution risk for longer-term commercialization initiatives absent sustained cash-flow improvement.
Early-stage Commercialization And Mix-driven Margin PressureNew products (Cohealyx, PermeaDerm) are in early adoption and currently lower average reported margins, driving mix-related margin decline. The company must convert limited early traction into scale; until adoption broadens, reported margins and profitability will remain pressured despite attractive RECELL unit economics.
Avita Medical News
RCEL FAQ
What was Avita Medical Ltd’s price range in the past 12 months?
Avita Medical Ltd lowest stock price was $3.22 and its highest was $7.12 in the past 12 months.
What is Avita Medical Ltd’s market cap?
Avita Medical Ltd’s market cap is $120.34M.
When is Avita Medical Ltd’s upcoming earnings report date?
Avita Medical Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 52 days.
How were Avita Medical Ltd’s earnings last quarter?
Avita Medical Ltd released its earnings results on May 14, 2026. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.292 by -$0.058.
Is Avita Medical Ltd overvalued?
According to Wall Street analysts Avita Medical Ltd’s price is currently Undervalued.
Does Avita Medical Ltd pay dividends?
Avita Medical Ltd does not currently pay dividends.
What is Avita Medical Ltd’s EPS estimate?
Avita Medical Ltd’s EPS estimate is -0.31.
How many shares outstanding does Avita Medical Ltd have?
Avita Medical Ltd has 30,776,690 shares outstanding.
What happened to Avita Medical Ltd’s price movement after its last earnings report?
Avita Medical Ltd reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.292. Following the earnings report the stock price went up 4.587%.
Which hedge fund is a major shareholder of Avita Medical Ltd?
Currently, no hedge funds are holding shares in RCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avita Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.17 (49.31% Upside)
$7.17 (49.31% Upside)
Blogger Sentiment
Bullish
RCEL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 14.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $205.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.58%
12-Months-Change
Fundamentals
Return on Equity
305.45%
Trailing 12-Months
Asset Growth
-25.90%
Trailing 12-Months
Company Description
Avita Medical Ltd
AVITA Medical, Inc. is a leading company focused on regenerative tissue, actively commercializing its innovative products across the United States, Australia, and the United Kingdom. The company's mission is to fulfill critical medical needs in areas such as severe burn and trauma injuries, chronic wounds, and various dermatological and aesthetic concerns, including vitiligo. At the core of its operations is a patented and proprietary technology platform that harnesses the natural regenerative properties found within a patient's own skin to develop therapeutic solutions. Their flagship product, the RECELL System, is a sophisticated medical device. It allows healthcare providers to prepare a suspension of "Spray-On Skin" cells directly from a small sample of the patient's healthy skin. This pioneering treatment is primarily approved for use in adults aged eighteen and older who have sustained acute thermal burns. Beyond its commercial activities, AVITA Medical is deeply invested in forward-thinking research. The company has a partnership with the University of Colorado School of Medicine, dedicated to exploring the preclinical viability of a spray-on application for genetically corrected cells. Furthermore, a collaboration with the Houston Methodist Research Institute aims to investigate the molecular processes involved in reversing cellular aging through an advanced cell suspension delivery system. Founded in 2000 and headquartered in Valencia, California, the company previously operated as AVITA Therapeutics, Inc. before officially changing its name to AVITA Medical Inc. in December 2020.
RCEL Company Deck
RCEL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple positive operational and commercial developments: sequential and year-over-year revenue growth, reduced operating expenses, improving net loss, RECELL reimbursement normalization, encouraging Cohealyx clinical data, BARDA partnership, and a credit facility structured with meaningful covenant headroom. Offsetting these positives are margin pressure from product mix and inventory reserves, a seasonal cash burn with a modest cash balance, and the early-stage commercialization risk of Cohealyx and PermeaDerm requiring further adoption and data to realize scale. Overall, the company appears to be transitioning from stabilization to execution with tangible early momentum but still faces near-term cash and margin headwinds as new products scale.View all RCEL earnings summariesRCEL Revenue Breakdown
99.27% Commercial sales
0.67% Services for emergency preparedness
0.07% Deferred commercial revenue
RCEL Stock 12 Month Forecast
Average Price Target
$7.17
▲(49.31% Upside)
Technical Analysis
Ownership Overview
1.87% Insiders
6.53% Mutual Funds
0.61% Other Institutional Investors
84.55% Public Companies and
Individual Investors